MIRA INFORM REPORT

 

 

Report Date :

28.09.2012

 

IDENTIFICATION DETAILS

 

Name :

TITAN LABORATORIES PRIVATE LIMITED

 

 

Registered Office :

102, Titan House, 60 Feet Road, M.P. Vidhya Marg, Ghatkopar (East), Mumbai - 400 077, Maharashtra

 

 

Country :

India

 

 

Financials (as on) :

31.03.2011

 

 

Date of Incorporation :

14.06.2004

 

 

Com. Reg. No.:

11-146928

 

 

Capital Investment / Paid-up Capital :

Rs.19.681 millions

 

 

CIN No.:

[Company Identification No.]

U24100MH2004PTC146928

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

MUMM22848A

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Manufactures of Sustained and Modified Release Pellets, DC Granules and Taste Mask Granules.

 

 

No. of Employees :

60 (Approximately)

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B (36)

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Maximum Credit Limit :

USD 337000

 

 

Status :

Moderate

 

 

Payment Behaviour :

Unknown

 

 

Litigation :

Clear

 

 

Comments :

Subject is a established company having moderate track. The financial detail for the current year is missing from government department. However, from previous year record company having satisfactory track. Trade relations are reported to be fair. Business is active. Payment terms are unknown.

 

The company can be considered for business dealings with some caution.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – June 30, 2012

 

Country Name

Previous Rating

(31.03.2012)

Current Rating

(30.06.2012)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

INDIAN ECONOMIC OVERVIEW

 

India is developing into an open-market economy, yet traces of its past autarkic policies remain. Economic liberalization, including industrial deregulation, privatization of state-owned enterprises, and reduced controls on foreign trade and investment, began in the early 1990s and has served to accelerate the country's growth, which has averaged more than 7% per year since 1997. India's diverse economy encompasses traditional village farming, modern agriculture, handicrafts, a wide range of modern industries, and a multitude of services. Slightly more than half of the work force is in agriculture, but services are the major source of economic growth, accounting for more than half of India's output, with only one-third of its labor force. India has capitalized on its large educated English-speaking population to become a major exporter of information technology services and software workers. In 2010, the Indian economy rebounded robustly from the global financial crisis - in large part because of strong domestic demand - and growth exceeded 8% year-on-year in real terms. However, India's economic growth in 2011 slowed because of persistently high inflation and interest rates and little progress on economic reforms. High international crude prices have exacerbated the government's fuel subsidy expenditures contributing to a higher fiscal deficit, and a worsening current account deficit. Little economic reform took place in 2011 largely due to corruption scandals that have slowed legislative work. India's medium-term growth outlook is positive due to a young population and corresponding low dependency ratio, healthy savings and investment rates, and increasing integration into the global economy. India has many long-term challenges that it has not yet fully addressed, including widespread poverty, inadequate physical and social infrastructure, limited non-agricultural employment opportunities, scarce access to quality basic and higher education, and accommodating rural-to-urban migration.

Source : CIA

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

 

LOCATIONS

 

Registered Office :

102, Titan House, 60 Feet Road, M.P. Vidhya Marg, Ghatkopar (East), Mumbai - 400 077, Maharashtra, India  

Tel. No.:

91-22-67857000

Fax No.:

91-22-67857070

E-Mail :

info@titan-lab.com

rjshah_ca@yahoo.com

 

Marketing Email:

titanpharmaindia@hotmail.com

info@titanpharma.com

 

HR Email :       

Mr. Sadashiv-hrd1@titanpharma.com

Ms. Arti-hrd2@titanpharma.com

 

Purchase Email :        

Mr. Rushab-purchase@titanpharma.com

Mr. Rakesh-purchase.ho@titanpharma.com

Website :

www.titan-lab.com

Location :

Rented

 

 

Corporate Office :

210, A Wing, Kahara Business Centre, Behind Everest Garden Building, Laxmi Nagar, Ghatkopar (East), Mumbai - 400 075, Maharashtra, India

Tel. No.:

91-22-67974849/ 67974850/ 67974852/ 55974850

Fax No.:

91-22-67974851/ 25006678

E-Mail :

info@titan-lab.com

Website:

www.titan-lab.com

 

 

Factory :

Plot No. E 27-1, E 27-2, MIDC Mahad, Village Jite, District Raigad, Maharashtra, India

Location :

Leased

 

 

DIRECTORS

 

As on 10.09.2011

 

Name :

Mr. Bhailal Babulal Shah

Designation :

Director    

Address :

601-602, Titan House, M.P. Vaidya Marg, Opposite Bank of Maharashtra, Ghatkopar (East), Mumbai – 400077, Maharashtra, India

Date of Birth/Age :

02.09.1945

Date of Appointment :

01.04.2008 

DIN No.:

00133479

Other Directorship :

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

L99999GJ1992PLC018156

TONIRA PHARMA LIMITED

Director

26/03/2009

13/08/1992

-

Amalgamated

NO

2

L65910GJ1995PLC024091

TIRUPATI SARJAN LIMITED

Director

11/10/1995

11/10/1995

-

Active

NO

3

U24239GJ2008PTC052906

TITAN BIOSCIENCE PRIVATE LIMITED

Director

13/02/2008

13/02/2008

-

Active

NO

4

U24100MH2004PTC146928

TITAN LABORATORIES PRIVATE LIMITED

Director

01/04/2008

01/04/2008

-

Active

NO

5

U51909GJ1995PLC025592

TONIRA EXPORTS LIMITED

Director

06/08/2010

10/12/2009

-

Active

NO

 

 

Name :

Mr. Piyush Bhailal Shah

Designation :

Director

Address :

601-602, Titan House, M.P. Vaidya Marg, Opposite Bank of Maharashtra, Ghatkopar (East), Mumbai – 400077, Maharashtra, India

Date of Birth/Age :

05.12.1977

Date of Appointment :

14.06.2004

DIN No.:

00606740

Other Directorship :

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U24234MH2001PTC133316

TITAN PHARMA (INDIA ) PRIVATE LIMITED

Director

09/10/2001

09/10/2001

-

Active

NO

2

U24100MH2004PTC146928

TITAN LABORATORIES PRIVATE LIMITED

Director

14/06/2004

14/06/2004

-

Active

NO

 

 

Name :

Mr. Virendra Babulal Shah

Designation :

Director    

Address :

601-602, Titan House, M.P. Vaidya Marg, Opposite Bank of Maharashtra, Ghatkopar (East), Mumbai – 400077, Maharashtra, India

Date of Birth/Age :

26.02.1953

Date of Appointment :

29.09.2005

DIN No.:

02044691

Other Directorship :

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U24100MH2004PTC146928

TITAN LABORATORIES PRIVATE LIMITED

Director

29/09/2005

29/09/2005

-

Active

NO

2

AAA-9436

CLOUDFRONTS TECHNOLOGIES LLP

Designated Partner

01/06/2012

01/06/2012

-

Active

NO

 

 

Name :

Mr. Deepak Bhailal Shah

Designation :

Director    

Address :

601-602, Titan House, M.P. Vaidya Marg, Opposite Bank of Maharashtra, Ghatkopar (East), Mumbai – 400077, Maharashtra, India

Date of Birth/Age :

24.03.1980

Date of Appointment :

01.04.2008

DIN No.:

02051891

Other Directorship :

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U24234MH2001PTC133316

TITAN PHARMA (INDIA ) PRIVATE LIMITED

Director

09/10/2001

09/10/2001

-

Active

NO

2

U24100MH2004PTC146928

TITAN LABORATORIES PRIVATE LIMITED

Director

01/04/2008

01/04/2008

-

Active

NO

 

 

Name :

Ms. Hiromi Deepak Shah

Designation :

Director    

Address :

601-602, Titan House, M.P. Vaidya Marg, Opposite Bank of Maharashtra, Ghatkopar (East), Mumbai – 400077, Maharashtra, India

Date of Birth/Age :

01.02.1980

Date of Appointment :

29.09.2005

DIN No.:

02134510

Other Directorship :

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U24234MH2001PTC133316

TITAN PHARMA (INDIA ) PRIVATE LIMITED

Director

09/10/2001

09/10/2001

-

Active

NO

2

U24100MH2004PTC146928

TITAN LABORATORIES PRIVATE LIMITED

Director

29/09/2005

29/09/2005

-

Active

NO

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on: 18.09.2012

 

Names of Shareholders

 

 

No. of Shares

Bhailal B. Shah jointly with Ranjan B. Shah

 

510600

Piyush B. Shah jointly with Jigna P. Shah

 

614600

Deepak B Shah jointly with Hiromi D. Shah

 

462600

Jigna P. Shah jointly with Piyush B. Shah

 

67500

Hiromi D. Shah jointly with Deepak B. Shah

 

100500

Ranjan B. Shah jointly with Bhailal B. Shah

 

133300

Ranjan B. Shah jointly with Deepak B. Shah

 

79000

 

 

 

Total

 

1968100

 

As on: 18.09.2012

 

Equity Share Breakup

 

Percentage of Holding

Category

 

 

Directors or relatives of directors

 

100.00

Total

 

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufactures of Sustained and Modified Release Pellets, DC Granules and Taste Mask Granules.

 

 

Products :

Generic Names of principal Products of Company

Item Code No. (ITC Code)

Product Description

29331190

Lansoprazole Pellets

29420090

Bulk Drugs

 

PRODUCTION STATUS (AS ON 31.03.2011)

 

Details of Capacity

Licensed Capacity

 

Installed Capacity

Pellets

108 M.T.

108 M.T.

 

 

Particulars

Actual Production

Qty.

Omerprazole E/C Pellets

5854.74

Tamsulosin HCL SR Pellets

2117.78

Pantoprazole Pellets

1.00

Domperidone Pellets

5664.25

Orlistat Pellets

10701.00

 

 

GENERAL INFORMATION

 

No. of Employees :

60 (Approximately)

 

 

Bankers :

v      HDFC Bank Limited

v      Union Bank of India, Khand Bazar Branch, 109, Kazi Sayed Street, Khand Bazar, Mumbai - 400 003, Maharashtra, India

 

 

Facilities :

Secured Loans

31.03.2011

Rs. In Millions

31.03.2010

Rs. In Millions

Union Bank of India – FCTL

 

 

- P/C Loan A/c No.00015

0.000

8.880

- Cash Credit A/c No.90026

14.151

2.683

- Bill Discounted with Bank

0.000

0.000

Union Bank of India

 

 

- Term Loan A/c (18115)

2.460

3.279

- Term Loan A/c (18116)

19.062

24.509

- Term Loan A/c (18117)

5.914

1.525

(All secured by equitable mortgage by deposit of title deeds in respect of land, building, machinery, furniture, fixtures and other fixed assets at Mahad and collaterally secured  by personal properties belonging for directors and their relatives and office premises belonging to a company in which directors are interested)

 

 

HDFC Bank Limited

(Secured against Hypothecation of Vehicle)

0.159

0.330

Total

41.746

41.206

 

Unsecured Loans

31.03.2011

Rs. In Millions

31.03.2010

Rs. In Millions

Loans from Directors

12.837

21.786

Loans from Members and Relatives of Directors

41.402

14.485

Inter Corporate Loans

0.010

0.020

Total

54.249

36.291

 

 

 

Banking Relations :

--

 

 

Auditors :

 

Name :

Rajesh J. Shah and Associates

Chartered Accountants 

Address :

B-401-404, 4th Floor, Rajshree Avenue, Near Dinesh Hall, Income Tax, Ahmedabad – 380 009, Gujarat, India

Tel. No.:

91-79-26580664/ 26580765

Mobile No.:

91-9824045695 (RJS)

91-9426008343 (KBP)

Fax No.:

91-79-26580765

E-Mail :

rjshah_ca@yahoo.com

PAN No.:

AADFR0856J

 

 

CAPITAL STRUCTURE

 

As on: 18.09.2012

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

2000000

Equity Shares

Rs.10/- each

Rs.20.000 millions

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

1968100

Equity Shares

Rs.10/- each

Rs.19.681 millions

 

 

 

 

 


 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2011

31.03.2010

31.03.2009

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

19.681

19.681

19.681

2] Share Application Money

0.000

0.000

0.000

3] Reserves & Surplus

64.471

27.817

2.607

4] (Accumulated Losses)

0.000

0.000

0.000

NETWORTH

84.152

47.498

22.288

LOAN FUNDS

 

 

 

1] Secured Loans

41.746

41.206

42.227

2] Unsecured Loans

54.249

36.291

8.898

TOTAL BORROWING

95.995

77.497

51.125

DEFERRED TAX LIABILITIES

27.716

8.427

4.303

 

 

 

 

TOTAL

207.863

133.422

77.716

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

159.916

86.446

73.066

Capital work-in-progress

0.000

0.000

0.000

 

 

 

 

INVESTMENT

2.435

0.000

0.000

DEFERRED TAX ASSETS

0.000

0.000

0.000

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

39.654

25.924

17.999

 

Sundry Debtors

49.611

36.770

32.258

 

Cash & Bank Balances

112.529

68.902

0.287

 

Other Current Assets

0.000

0.000

0.000

 

Loans, Advances & Deposits

43.804

19.862

6.753

Total Current Assets

245.598

151.458

57.297

Less : CURRENT LIABILITIES & PROVISIONS

 

 

 

 

Sundry Creditors

162.604

73.847

43.782

 

Other Current Liabilities

26.884

24.038

4.284

 

Provisions

10.598

6.733

4.740

Total Current Liabilities

200.086

104.618

52.806

Net Current Assets

45.512

46.840

4.491

 

 

 

 

MISCELLANEOUS EXPENSES

0.000

0.136

0.159

 

 

 

 

TOTAL

207.863

133.422

77.716

 


PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2011

31.03.2010

31.03.2009

 

SALES

 

 

 

 

 

Income

NA

449.968

161.500

 

 

Other Income

NA

1.957

3.678

 

 

TOTAL                                    

NA

451.925

165.178

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Office Expenses

NA

417.698

153.501

 

 

Administrative Expenses

 

 

 

 

 

Advertising Expenses

 

 

 

 

 

TOTAL                        

NA

417.698

153.501

 

 

 

 

 

 

PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION

NA

34.227

11.677

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                    

NA

3.906

3.204

 

 

 

 

 

 

PROFIT BEFORE TAX

NA

30.321

8.473

 

 

 

 

 

Less

TAX                                                                 

NA

5.111

5.632

 

 

 

 

 

 

PROFIT AFTER TAX

NA

25.210

2.841

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

588.448

412.242

139.430

 

 

 

 

 

 

Earnings Per Share (Rs.)

NA

12.81

1.44

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2011

31.03.2010

31.03.2009

PAT / Total Income

(%)

NA

5.58

1.72

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

NA

6.74

5.25

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

NA

12.75

6.50

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

NA

0.64

0.38

 

 

 

 

 

Debt Equity Ratio

(Total Liability/Networth)

 

3.52

3.83

4.66

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

1.23

1.45

1.09

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

Yes

9]

Name of person contacted

No

10]

Designation of contact person

No

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

--

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

No

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

No

20]

Export / Import details (if applicable)

No

21]

Market information

--

22]

Litigations that the firm / promoter involved in

--

23]

Banking Details

Yes

24]

Banking facility details

Yes

25]

Conduct of the banking account

--

26]

Buyer visit details

--

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

No

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

Yes

32]

PAN of Proprietor/Partner/Director, if available

No

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

No

 

Note:

The registered office of the company has been shifted from 210, A Wing, Kahara Business Centre, Behind Everest Garden Building, Laxmi Nagar, Ghatkopar (East), Mumbai 400 075, Maharashtra to the present address w.e.f. 19.09.2009.

 

 

Bankers Charges Report as per Registry

 

Corporate identity number (CIN) or foreign company

registration number of the company

U24100MH2004PTC146928

Name of the company

TITAN LABORATORIES PRIVATE LIMITED

Address of the registered office or of the principal place of  business in India of the company

102, Titan House, 60 Feet Road, M.P. Vidhya Marg, Ghatkopar (East), Mumbai - 400 077, Maharashtra, India

E-mail: info@titan.lab.com

This form is for

Modification of charge

Charge identification (ID) number of the charge to be modified

90351989

Type of charge

Immovable property

Particular of charge holder

Union Bank of India, Khand Bazar Branch, 109, Kazi Sayed Street, Khand Bazar, Mumbai - 400 003, Maharashtra, India

E-mail: cbskhandbazar@unionbankofindia.com

Nature of instrument creating charge

Extension of Equitable Mortgage

Date of instrument Creating the charge

12.11.2011

Amount secured by the charge

Rs.67.377 Millions

Brief of the principal terms an conditions and extent and operation of the charge

Rate of Interest

Together with interest compound interest additional interest in case of default liquidated damages commitment charges premia on repayment or redemption cost charges expenses etc

 

Terms of Repayment

Working Capital facilities on Demand and Term Loan in installments as fixed by the Bank

 

Margin

As per sanction terms

 

Extent and Operation of the charge

To additionally secure various revised credit facilities aggregating to Rs.67.377 Millions granted by the Bank to the Company as under :-

1.FDBP/FUDBP (60-90 Days ) Rs.30.000 Millions W/W

Packing Credit of  Rs.30.000 Millions W/W Imp/Inl L/C. Rs.30.000 Millions W/W Buyers Credit Rs.30.000 Millions

2.AFDBC Rs. 2.500 Millions

3.CC Hyp Rs.3.000.Millions

4 Term Loan   Rs. 9.500 Millions

5. Term Loan FCTL Rs.19.516 Millions

6. Term Loan Crystalised FCTL Rs.2.509 Millions

7.Letter of Guarantee  Rs.0.352 Million

Total aggregating to Rs.67.377 Millions

Short particulars of the property or asset(s) charged (including complete address and location of the property)

Extension of Equitable Mortgage by Deposit of Title Deeds by Oral Consent in respect of Company's Immovable Properties  viz.

A. All that Piece or Parcel of land totally adm about 8768 Sq. Mtrs being 1.Plot No.E-27/1 admeasuring about 3723 Sq. Mtrs and 2. Plot No. E-27/2 admeasuring about 5045 Sq. Mtrs. situated in the Mahad Industrial Area within the Village limits of the Jite and outside the limits of Mahad Municipal Council, Taluka and Registration Sub-District Mahad, District and Registration District of Raigad in the name of Titan Laboratories Private Limited bounded as follows On or towards the North by Nalla and Strip

On or towards the South by Plot No.E-27/3

On or towards the East by MIDC Road

On or towards the West by Nalla

B. Unit No.310 admeasuring 404 Sq.ft (carpet) on the third floor A Wing of the Industrial Estate known as Kanara Business Centre situate at Pant Nagar Ghatkopar (East) Mumbai 400075 Village limit of Ghatkopar Kirol, Taluka Kurla CTS No.5365 Registration District of Mumbai Suburban in the name of Titan Laboratories Private Limited

Date of instrument modifying the charge

09.11.2010

Particulars of the present modification

Vide this modification the charge amount enhanced from 60.350 Millions to 67.377 Millions by addition of 7.027 Millions and secured against Extension of Equitable Mortgage in respect of Company's Immovable Properties viz.

A. All that Piece or Parcel of land totally admeasuring about 8768 Sq.Mtrs being 1.Plot No.E-27/1 and 2. Plot No. E-27/2  situated in the Mahad industrial Area

B. Unit No.310 adm 404 Sq.ft (carpet) on the 3rd floor "A" wing of the Kanara Business Centre .

 

 

 

Fixed Assets:

 

·         Land at Mahad

·         Factory Building - mahad

·         Electrical Fitting – Mahad

·         Electrical Fitting – Office

·         Plant and Machinery

·         Laboratory Equipments

·         Factory Equipments

·         Air Conditioner

·         Compressor

·         Refrigerator

·         Furniture and Fixture – Mahad

·         Furniture and Fixture – Office

·         Office Premises

·         Computer and Printers

·         Water Purifier

·         Air Conditioner – Titan House

·         Water Purifier – Titan House

·         Electrical Fitting – Titan House

·         Furniture and Fixture – Titan House

·         Office Equipments – Titan House

·         Motor Car

 

WEBSITE DETAILS:

 

PROFILE:

 

Subject is the one of select few Company in India with dedicated state of art WHO GMP facility for producing high quality Sustained and Modified Release Pellets, DC Granules and Taste Masked Granules. The plant is Located in green belt of Mahad industrial zone about 180Kms from Mumbai. It is strategically located on well connected Mumbai-Goa Highway.

 

Subject is a speciality Pharmaceutical company engaged in developing and manufacturing Sustained and Modified Release Pellets using Innovative Drug Delivery Technologies Utilizing some of best and latest processing machineries like Fluid Bed Processor with inherent built in rotary unit coupled with Top And Bottom Spray arrangement. This is essential to achieve uniformity and efficiency in layering and/ coating process which in turn will ensure in consistent release characteristics. Facility of Extruder and spheronizer is also available for effective pelletizing selectivity depending upon dose requirements of actives.

 

Their specialized product development needs are well service by In-house R and D facilities comprising of Formulation and Analytical competencies.

 

The CGMP led manufacturing facility is approved by Indian Drug Authorities, while they are in state of preparedness for impending customer triggered inspection from their foreign clients. These activities are ably supported by their QA and Regulatory set-up for country /customer specific needs.

 

The Company’s Drug Delivery System development thrust is based on following principles

 

v      Off Patent Generics

v      Custom development

v      Process Patenting of Technologies

v      Customized Release as per Pharmacokinetic profile

 

Salient Features of Manufacturing Facility

v      Manufacturing facilities designed to conform to EU and FDA cGMP regulations.

v      Three manufacturing modules – one for high volume products; other 2 for low volume products.

v      Capsulation section for Commercial Supply under P2P and Loan License .

v      Purified water distribution Pipeline from GEORGE FISCHER Switzerland. PLC based distribution system

v      Facilities conform to class 100,000 requirements, up-gradable to class 10,000.

 

Business Model

v      Supply of pellets and granules in bulk

v      Development of formulation dossiers

v      Joint venture from development to commercialization of products

v      Contract manufacturing for pellets and finished form (capsules)

v      Out license manufacturing technology

 

Technical package is available for each product and DMF (CTD format) is ready for key products. They are interested in developing new products exclusively for customer specific needs and produce them on commercial scale.

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No records exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                  None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.53.26

UK Pound

1

Rs.86.23

Euro

1

Rs.68.64

 

 

INFORMATION DETAILS

 

Report Prepared by :

VRN


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

4

PAID-UP CAPITAL

1~10

4

OPERATING SCALE

1~10

4

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

4

--PROFITABILIRY

1~10

4

--LIQUIDITY

1~10

4

--LEVERAGE

1~10

4

--RESERVES

1~10

4

--CREDIT LINES

1~10

4

--MARGINS

-5~5

-

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

NO

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

TOTAL

 

36

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

-

NB

                                       New Business

-

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.